GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00082511
Recruitment Status : Completed
First Posted : July 16, 2004
Last Update Posted : January 14, 2008
Information provided by:
Genelabs Technologies

Brief Summary:
Open label safety and efficacy follow-up.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Prasterone (GL701) Phase 3

Detailed Description:
This was a randomized, multi-center, open-label, parallel-group, trial of prasterone 200 or 100 mg/day for 12 months in women with lupus receiving glucocorticoid therapy who had completed an earlier 6-month randomized, placebo-controlled study (NCT00053560. Bone Mineral Density assessments were performed at baseline and at months 6 and 12.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Study Start Date : July 2003
Actual Primary Completion Date : August 2005
Actual Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus Steroids
Drug Information available for: Prasterone

Intervention Details:
  • Drug: Prasterone (GL701)

    There were 4 arms to the study:

    During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.

Primary Outcome Measures :
  1. Maintenance of bone mineral density (BMD) in women with systemic lupus erythematosus receiving glucocorticoids. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has completed the full 6 month treatment period with study drug in the previous Genelabs' clinical study GL02-01.
  • Concomitant treatment with prednisone (or equivalent) at a dose of ≥ 5mg/day.
  • Patient has read and signed an Informed Consent Form. If the patient is not fluent in English, the Informed Consent must be signed in her native language.

Exclusion Criteria:

  • Patient has had a serious study drug related adverse reaction at any time during the previous GL02-01 study.
  • Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease).


  • Calcitonin
  • Bisphosphonates
  • Fluoride at pharmacologic dose
  • Strontium at pharmacologic dose
  • Estrogenic steroids (except oral contraceptives)
  • Selective Estrogen Receptor Modulator (raloxifene)
  • Parathyroid hormone
  • Any androgens, including prescription or nutritional supplement DHEA, other than study drug
  • Additional Calcium supplements other than those prescribed as part of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00082511

United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85724
United States, California
Wallace Rheumatic Study Center
Los Angeles, California, United States, 90048
Lifestyles Health Science Center
Rancho Mirage, California, United States, 92270
University of California San Diego
San Diego, California, United States, 92093-0943
East Bay Rheumatology Group
San Leandro, California, United States, 94578
United States, Florida
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, United States, 33334
Rheumatology Associates of Central Florida
Orlando, Florida, United States, 32806-6264
Tampa Medical Group, P.A.
Tampa, Florida, United States, 33614
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21205
United States, Missouri
St. John's Medical Research Group
Springfield, Missouri, United States, 65804
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Albert Einstein Medical School
Bronx, New York, United States, 10461
SUNY Downstate Medical Center
Brooklyn, New York, United States, 11203
North Shore University Hospital, Division of Rheumatology
Manhasset, New York, United States, 11030
United States, Oklahoma
Oklahoma Center for Arthritis Therapy
Tulsa, Oklahoma, United States, 74114
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97201
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
United States, Virginia
Sentara Medical Group DBA
Virginia Beach, Virginia, United States, 23462
United States, Washington
Seattle Rheumatology Associates
Seattle, Washington, United States, 98104
Immunology/Rheumatology Instituto Nacional de Ciencias Medicas y Nutricion, S.Z.
Mexico City, Mexico, 14000
Sponsors and Collaborators
Genelabs Technologies

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kenneth E. Schwartz, MD, Genelabs Technologies, Inc. Identifier: NCT00082511     History of Changes
Other Study ID Numbers: GL03-01
First Posted: July 16, 2004    Key Record Dates
Last Update Posted: January 14, 2008
Last Verified: January 2008

Keywords provided by Genelabs Technologies:
Systemic Lupus Erythematosus
Bone Loss

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Adjuvants, Immunologic
Immunologic Factors